[HTML][HTML] The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver
H Shah, M Bilodeau, KW Burak, C Cooper, M Klein… - Cmaj, 2018 - Can Med Assoc
The treatment of hepatitis C has become safer, better tolerated and more effective owing to
the availability of direct-acting antivirals for nearly all patients; this guideline advocates …
the availability of direct-acting antivirals for nearly all patients; this guideline advocates …
Population health and cost-effectiveness implications of a “treat all” recommendation for HCV: a review of the model-based evidence
LE Cipriano, JD Goldhaber-Fiebert - MDM policy & practice, 2018 - journals.sagepub.com
The World Health Organization HCV Guideline Development Group is considering a “treat
all” recommendation for persons infected with hepatitis C virus (HCV). We reviewed the …
all” recommendation for persons infected with hepatitis C virus (HCV). We reviewed the …
Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review
J Puig-Junoy, N Pascual-Argente… - Expert review of …, 2018 - Taylor & Francis
Introduction: High prices of second-generation direct-acting antivirals (DAAs) in the
treatment of chronic hepatitis C virus (HCV) patients led to reimbursement decisions based …
treatment of chronic hepatitis C virus (HCV) patients led to reimbursement decisions based …
[HTML][HTML] The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon's multiple streams framework
Abstract Background Hepatitis C virus (HCV) infection causes a large number of deaths
annually worldwide. Policies play an important role in regulating healthcare agendas and …
annually worldwide. Policies play an important role in regulating healthcare agendas and …
Feasibility of hepatitis B elimination in high-income countries with ongoing immigration
Background & Aims Addressing HBV is vital to meeting the World Health Organization
(WHO)'s viral hepatitis elimination goals, as 47% of viral hepatitis complications can be …
(WHO)'s viral hepatitis elimination goals, as 47% of viral hepatitis complications can be …
Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada
F Tian, SKD Houle, MW Alsabbagh, WWL Wong - Pharmacoeconomics, 2020 - Springer
Abstract Background/Aim Tenofovir alafenamide (TAF) has been approved for treating
chronic hepatitis B (CHB) due to a proposed better safety profile in comparison with current …
chronic hepatitis B (CHB) due to a proposed better safety profile in comparison with current …
Model-based projection of health and economic effects of screening for hepatitis C in Canada
Background: Because most hepatitis C virus (HCV) infections are asymptomatic and often
unrecognized, screening for hepatitis C has been proposed as a plausible public health …
unrecognized, screening for hepatitis C has been proposed as a plausible public health …
Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study
WWL Wong, A Haines, KE Bremner, Z Yao… - … Open Access Journal, 2021 - cmajopen.ca
Background: High-quality estimates of health care costs are required to understand the
burden of illness and to inform economic models. We estimated the costs associated with …
burden of illness and to inform economic models. We estimated the costs associated with …
[HTML][HTML] A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in …
Managing chronic hepatitis C is challenging, as the majority of those infected are
asymptomatic. Therefore, to ensure treatments are administered before the onset of severe …
asymptomatic. Therefore, to ensure treatments are administered before the onset of severe …
Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings
WWL Wong, J Wong, KE Bremner, Y Saeed… - Liver …, 2023 - Wiley Online Library
Background Direct‐acting antiviral agents (DAAs) have transformed chronic hepatitis C
(CHC) treatment. Continued affordable access to DAAs requires updated cost‐effectiveness …
(CHC) treatment. Continued affordable access to DAAs requires updated cost‐effectiveness …